Pfizer Finally Wins English Funding For Sickle Cell Drug Oxbryta After Bumpy Ride

 
• By Neena Brizmohun

After several rejections by NICE and an appeal by Pfizer, the company has reduced the price for its first-in-class sickle cell disease drug to a level that the health technology assessment institute deems acceptable.

3d rendered medical illustration of a sickle cell
Oxbryta will be funded immediately via England’s Innovative Medicines Fund. • Source: Shutterstock

More from Market Access

More from Pink Sheet